A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat

Min Hee Lee a, Ian J. Neeland b, Natalia de Albuquerque Rocha c, Connor Hughes d, Craig R. Malloy a, e, f, Eunsook S. Jin a, d, e, *

a Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
b Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
c Essentia Health Heart and Vascular Center, Duluth, MN, USA
d Department of Internal Medicine, University of Texas Southwestern Medical Center, USA
e Department of Radiology, University of Texas Southwestern Medical Center, USA
f VA North Texas Health Care System, Dallas, TX, 75216, USA

* Corresponding author. Advanced Imaging Research Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8568, USA.
E-mail address: Eunsook.Jin@utsouthwestern.edu (E.S. Jin).

ABSTRACT

Background: Empagliflozin, a sodium glucose cotransporter 2 inhibitor, is a medication to treat type 2 diabetes. The effect of empagliflozin in persons without diabetes has received less attention. Here we conducted a randomized, double-blind placebo-controlled clinical trial to examine the effect of empagliflozin on plasma triglycerides in obese non-diabetic adults.

Methods: Participants (n = 35; BMI ≥ 30 kg/m²) underwent body composition assessments using MRI, and were randomly assigned to either placebo or empagliflozin (10 mg/d) for three months. At the baseline and post-treatment visit, after an overnight fast, blood was drawn for biochemical analysis. Participants received [U-13C3]glycerol orally followed by multiple blood draws over 3 h to examine glycerol incorporation into triglycerides using NMR spectroscopy.

Results: The changes in blood triglyceride concentration with empagliflozin therapy related to the mass of baseline visceral adipose tissue (VAT; r = 0.53, p = 0.04). Empagliflozin slightly lowered triglycerides in obese subjects with low VAT, but increased triglycerides in the subjects with high VAT. Consistently, empagliflozin effectively suppressed triglyceride synthesis following [U-13C3]glycerol administration in the subjects with low VAT (p < 0.05), but not in the subjects with high VAT. The subjects with high VAT lost body weight after three months of empagliflozin treatment. In all subjects, about 20% of the triglyceride backbone originated from mitochondrial metabolism of glycerol.

Conclusions: The effect of empagliflozin on triglycerides in obese adults differed depending on VAT. Empagliflozin suppressed triglyceride synthesis in the subjects with low VAT, but tended to increase triglycerides in those with high VAT.

1. Introduction

Obesity threatens public health throughout the world because it is a risk factor for the development of multiple chronic diseases [1–3]. Visceral adipose tissue (VAT), triglyceride deposits lining internal organs, strongly associates with metabolic syndrome, type 2 diabetes mellitus (T2DM), hypertriglyceridemia, and cardiovascular disease [4–9]. Plasma triglycerides, VAT, lipogenesis and lipolysis are tightly linked to glucose metabolism. Lipolysis occurs when blood glucose is low while excess glucose is converted to triglycerides and stored as fatty tissue [10]. VAT may play a particularly important role in glucose production because it is metabolically highly active, and lipolysis in VAT releases both glycerol and free fatty acids directly into the portal circulation [11–13]. Thus, VAT provides an excellent substrate for gluconeogenesis, glycerol, and a source of energy for the metabolically-expensive process of gluconeogenesis.

Sodium glucose cotransporter 2 (SGLT2) inhibitors were developed to treat T2DM in combination with metformin or other conventional antihyperglycemic drugs [14]. The inhibitors enhance glycosuria by preventing glucose reabsorption in the kidney [15–17]. The impact of SGLT2 inhibitors on glucose metabolism in diabetic patients has been...
extensively studied [17–24]. They reduced fasting blood glucose and glycated hemoglobin (HbA1c), and improved insulin sensitivity and β cell function in diabetic patients. However, endogenous glucose production was increased to compensate for glycosuria [17]. Lipid metabolism with SGLT2 inhibitor therapy has been also investigated, but the results are controversial. The inhibitors led to body weight loss, and reduced VAT and liver fat in diabetic patients [18–22, 24]. The loss of blood glucose due to glycosuria is expected to increase glucagon secretion, which stimulates fatty acid oxidation and consequently reduces body fat content [25–27]. However, several earlier studies with diabetic patients also reported dyslipidemia associated with SGLT2 inhibitor therapy [28–30].

Empagliflozin is a highly selective inhibitor of SGLT2 [31]. Single doses of empagliflozin inhibited up to 60% of filtered glucose reabsorption in healthy subjects [32]. Empagliflozin also increased 13C-labeled glucose in blood after [U-13C3]glycerol ingestion in our recent study with non-diabetic obese adults, suggesting reduced gluconeogenesis from unlabeled glycerol derived from VAT [33]. However, little additional information is available regarding the effects of SGLT2 inhibitors in obese, non-diabetic subjects. Since we did not investigate the impact of empagliflozin on triglycerides previously, we acquired additional 13C nuclear magnetic resonance (NMR) spectra from the non-aqueous metabolites in plasma to determine whether there is an interaction between VAT and the effects of empagliflozin on plasma triglyceride concentration. MRI was used to measure baseline VAT and other aspects of body composition. NMR analysis was performed to monitor triglyceride synthesis from orally-administered [U-13C3]glycerol and to assess the glycerol metabolism through the TCA cycle in mitochondria.

**Fig. 1. Study procedures.** (A) Participants (n = 40) were randomly assigned to either placebo or empagliflozin. Three subjects from the placebo group and two from the empagliflozin group dropped out, and 17 volunteers in the placebo group and 18 in the empagliflozin group completed the study. (B) Participants made four visits with 4-week intervals. At the first visit after an overnight fast, MRI was performed for body composition measurement. Blood was drawn for biochemical analysis, and procedures with [U-13C3]glycerol were performed. Participants were assigned to either placebo or empagliflozin. At the second and the third follow-up visits, drug adherence and side effects were monitored. At the last visit after an overnight fast, blood was drawn for analysis and the procedures with [U-13C3]glycerol were performed. (C) At the first and the fourth visits, participants drank [U-13C3]glycerol-dissolved water and blood was drawn at multiple time points (15, 30, 60, 90, 120, 150 and 180 min) for NMR analysis of triglycerides.

### Abbreviations

| Abbreviation | Definition                  |
|--------------|-----------------------------|
| ALT          | alanine aminotransferase    |
| BMI          | body mass index             |
| FFAs         | free fatty acids            |
| FGF          | fibroblast growth factor    |
| HbA1c        | glycated hemoglobin        |
| GK           | glycerol kinase             |
| G3P          | glycerol 3-phosphate        |
| MRI          | magnetic resonance imaging  |
| NMR          | nuclear magnetic resonance  |
| SAT          | subcutaneous adipose tissue |
| SGLT2        | sodium glucose cotransporter 2 |
| TCA          | tricarboxylic acid          |
| T2DM         | type 2 diabetes mellitus    |
| TG           | triglycerides               |
| VAT          | visceral adipose tissue     |

**2. Methods**

**2.1. Research design**

This study was approved by the Institutional Review Board at the University of Texas Southwestern Medical Center, and it was registered on ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT02833415). Healthy adults with BMI ≥ 30 kg/m² were recruited, but subjects with chronic illness including T2DM were excluded. Among 40 qualified...
participants initially, 35 volunteers (ages, 43–59 years; BMI, 32–40 kg/m²; 13 males and 22 females; 20 Caucasians, 12 African Americans and 3 others) completed this study (Fig. 1A and Table 1). The details of demographic and clinical characterization of participants were reported previously [33]. Each volunteer provided written informed consent prior to participation and visited four times spaced four weeks apart over three months (Fig. 1B). At the first visit after an overnight fast, body composition assessments were performed [33]. An intravenous catheter was positioned in an antecubital vein and blood was drawn for biochemical analysis at baseline. Participants ingested [U-13C3]glycerol (99%; Cambridge Isotope Laboratories, Tewksbury, MA; 50 mg/kg body weight) dissolved in water at 9:30 a.m. followed by a series of blood draws at 15, 30, 60, 90, 120, 150 and 180 min after the oral administration (Fig. 1C). At each time point, 40-mL of blood was drawn and blood was immediately centrifuged. Plasma was stored at –80 °C prior to further processing. Participants were randomly assigned to either empagliflozin (orally; 10 mg once daily; Boehringer Ingelheim, Germany) or placebo. The assignment was blinded to participants and investigators until all study procedures and data acquisition were completed. At the second and third visits, drug adherence and any adverse effects were assessed. At the fourth visit after an overnight fast, blood was drawn for analysis and the same procedures with [U-13C3]glycerol were performed completing the whole study.

### 2.2. Body fat measurement

Body fat measurement was performed at the first visit and the details were reported previously [33]. Briefly, the assessment was performed using a Phillips Achieva 3T MRI scanner (Philips Healthcare, Amsterdam, Netherlands) with the dual-echo Dixon Vibe protocol covering from the neck to knees, and multi-echo Dixon acquisition for fat assessment in the liver. A 16-channel SENSE XL Torso coil was used for the images of the liver and a body coil for the rest of the body. Image data were analyzed for VAT, liver fat and abdominal subcutaneous adipose tissue (SAT) using AMRA Profiler Research (AMRA Medical AB, Linköping, Sweden) [34–37].

### 2.3. Lipid extraction and NMR spectroscopy

Plasma (3 mL) was transferred into a 20-mL glass vial containing a mixture of chloroform and methanol (2:1; 12 mL). The mixture was

---

**Table 1**

| Characteristic                  | Placebo (n = 17) | Empagliflozin (n = 18) | p    |
|--------------------------------|-----------------|------------------------|------|
| Age (years)                    | 53.1 ± 2.2      | 50.4 ± 2.3             | 0.421|
| Male/Female                    | 6/11            | 7/11                   |      |
| Race (Black/White/Other)       | 7/9/1           | 5/11/2                 |      |
| Body weight (kg)               | 104.0 ± 3.1     | 99.4 ± 2.4             | 0.246|
| Body mass index (kg/m²)        | 36.5 ± 1.1      | 35.6 ± 0.8             | 0.522|
| Total body fat (%)             | 44.9 ± 2.3      | 42.6 ± 2.1             | 0.467|
| Total body lean mass (%)       | 24.5 ± 1.1      | 25.8 ± 1.1             | 0.424|
| Visceral fat (kg)              | 5.4 ± 0.5       | 5.5 ± 0.6              | 0.902|
| Abdominal subcutaneous fat (kg)| 14.4 ± 1.1      | 12.1 ± 1.1             | 0.150|
| Liver fat (%)                  | 9.0 ± 1.8       | 10.5 ± 1.7             | 0.539|
| Total thigh muscle (kg)        | 11.8 ± 0.8      | 11.6 ± 0.7             | 0.882|

Values are mean ± SE.

---

**Fig. 2. Glycerol incorporation to triglycerides.**

(A) Glycerol in the liver is converted to glycerol 3-phosphate (G3P), a necessary intermediate for fatty acid esterification. [U-13C3]glycerol direct incorporation through this process produces triglycerides containing triple-labeled glycerol backbone (i.e., TG-[13C3]glycerol). (B) A fraction of glycerol enters glycolytic pathways followed by the TCA cycle where carbons from [U-13C3]glycerol are scrambled, which generates 13C3-double labeled trioses that can be further converted to G3P for fatty acid esterification. [U-13C3]glycerol indirect contribution to triglycerides through the TCA cycle produces double-labeled glycerol backbone (i.e., TG-[13C2]glycerol). A doublet (D) at TG-glycerol C1 & C3 (62.2 ppm) is the signal from both TG-[13C2]glycerol and TG-[13C2]glycerol. In contrast, a doublet at TG-glycerol C2 (69.1 ppm) is the signal from TG-[13C2]glycerol while a triplet (T) is the signal from TG-[13C2]glycerol only. (C-D) According to 13C NMR of TG-glycerol, empagliflozin treatment reduced plasma triglycerides in a subject with low VAT (1.9 kg) after [U-13C3]glycerol administration while it increased the triglycerides in a subject with high VAT (5.4 kg). A singlet (S) at TG-glycerol C1&C3 reflects the concentration of triglycerides and all spectra were derived from blood drawn at 180 min after oral administration of [U-13C3]glycerol. Signals can be directly compared because they are scaled to an internal standard. GK, glycerol kinase; open circle & B; blue circle & C; black circle & D. For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
stirred for 30 min, centrifuged at a low speed, and the bottom chloroform layer was transferred to a new glass vial. The extraction was repeated after adding chloroform (8 mL) to the mixture in the first vial. After stirring and centrifugation, the chloroform layer was transferred and combined with the first one. Lipids extracted using chloroform were dried under vacuum with a liquid nitrogen trap. Dried lipids were dissolved in deuterated chloroform (CDCl₃, 170 μL) and transferred to a 3-mm tube for NMR acquisition.

NMR spectra of lipids were collected using a 14.1T spectrometer (Varian INOVA, Agilent, Santa Clara, CA) equipped with a 3-mm broadband probe with the observe coil tuned to ¹³C (150 MHz). Spectra were acquired using a 60° pulse, a 36,765-Hz sweep width, 110,294 data points and a 1.5-s sec acquisition time with 1.5-s inter-pulse delay at 25 °C. Proton decoupling was performed using a standard WALTZ-16 pulse sequence. Spectra were averaged at least 8000 scans requiring 7 h. All NMR spectra were analyzed using ACD/Labs NMR spectral analysis program (Advanced Chemistry Development, Inc., Toronto, Canada).

2.4. NMR analysis of triglycerides

Plasma lipids were analyzed using ¹³C NMR focusing on the glycerol backbone of triglycerides (i.e., TG-glycerol), as reported previously [38]. Glycerol in the liver is phosphorylated via glycerol kinase to generate glycerol 3-phosphate, the required precursor for fatty acid esterification producing triglycerides. Thus, the appearance of ¹³C-labeled glycerol in the backbone of triglycerides in plasma after [U-¹³C]glycerol administration is evidence of hepatic triglyceride synthesis from glycerol followed by triglyceride release into the circulation. The triglyceride backbone may be derived from glycerol through direct metabolism or indirectly via metabolism of glycerol through the TCA cycle followed by resynthesis to glycerol 3-phosphate. These pathways may be distinguished by ¹³C NMR spectroscopy as illustrate in Fig. 2.

Total ¹³C-enrichment in the backbone of triglycerides was quantified by ¹³C NMR analysis of TG-glycerol carbons 1 and 3 (C1 & C3) at 62.2 ppm (Fig. 2A). A doublet (D) in this region is the signal from triglycerides containing [U-¹³C]-, [1,2-¹³C]-, or [2,3-¹³C]glycerol, and a singlet (S) is essentially from triglycerides with natural abundance backbone (i.e., TG-[1,1-¹³C]glycerol or TG-[3-¹³C]glycerol). The total ¹³C-enrichment in TG-glycerol was calculated using the peak area of the doublet assuming the singlet as natural abundance (1.1%).

Glycerol incorporation directly vs. indirectly through the TCA cycle can be distinguished based on ¹³C-labeling patterns in TG-glycerol carbon 2 (C2) at 69.1 ppm (Fig. 2B). Direct incorporation of [U-¹³C]glycerol produces triglycerides with a triple-labeled backbone (i.e., TG-[1,2,3-¹³C]glycerol). Glycerol metabolism through the TCA cycle prior to incorporation into triglycerides produces a double-labeled backbone (i.e., TG-[1,2-¹³C]glycerol) due to ¹³C scrambling in the TCA cycle that produces double-labeled trioses [39]. In the ¹³C NMR spectrum of TG-glycerol C2, a doublet (D) is the signal from TG-[1,2-¹³C]glycerol and a triplet (T) is from TG-[1,3-¹³C]glycerol. Thus, the doublet and the triplet enable determination of glycerol metabolism to triglycerides via indirect and direct pathways, respectively. A double-labeled backbone in triglycerides is an index of mitochondrial biosynthetic function.

2.5. Biochemical assays

Assays for plasma insulin, HbA1c, TG, adiponectin, C-reactive protein, alanine aminotransferase (ALT), norepinephrine, free fatty acids and glycerol were performed by Quest Diagnostics (Irving, TX or San Juan Capistrano, CA). Glucose was measured using the glucose oxidase method (YSI 2300 Glucose Analyzer; GMI, Inc.). Glucagon and fibroblast growth factor (FGF) 21 were measured using ELISA assay kits (Merckodia, Winston-Salem, NC, and Abcam, Cambridge, MA, respectively).

Table 2 Biochemical characteristics of participants at baseline (1st visit, v1) and the final visit (4th visit, v4).

| Assay                        | Placebo (n = 17) | Empagliflozin (n = 18) | p    |
|------------------------------|-----------------|------------------------|------|
| Adiponectin (mcg/mL)         | v1 7.1 ± 1.1     | v4 8.4 ± 1.7           | 0.512|
| ALT (U/L)                    | v1 8.1 ± 1.6     | v4 7.5 ± 1.0           | 0.708|
| C-reactive protein (mg/dL)   | v1 23.6 ± 2.8    | v4 24.4 ± 3.3          | 0.896|
| C-reactive protein (mg/dL)   | v1 20.9 ± 1.8    | v4 21.0 ± 2.4          | 0.953|
| C-reactive protein (mg/dL)   | v1 1.2 ± 0.6     | v4 0.5 ± 0.1           | 0.213|
| FFA (mmol/L)                 | v1 0.7 ± 0.1     | v4 0.6 ± 0.1           | 0.145|
| FGF21 (ng/mL)                | v1 1.02 ± 0.15   | v4 1.22 ± 0.11         | 0.265|
| Glucose (mmol/L)             | v1 0.6 ± 0.1     | v4 0.6 ± 0.1           | 0.106|
| HbA1c (%)                    | v1 3.5 ± 0.9     | v4 2.2 ± 0.9           | 0.467|
| HOMA-IR                      | v1 3.9 ± 1.0     | v4 2.7 ± 0.6           | 0.278|
| Norepinephrine (pg/mL)       | v1 5.3 ± 0.2     | v4 5.3 ± 0.1           | 0.977|
| Triglycerides (mmol/L)       | v1 5.4 ± 0.1     | v4 5.2 ± 0.1           | 0.178|
| Glycerol (ng/mL)             | v1 15.4 ± 0.9    | v4 17.6 ± 2.4          | 0.386|
| HbA1c (%)                    | v1 15.7 ± 0.3    | v4 15.5 ± 0.5          | 0.909|
| Insulin (μIU/mL)             | v1 5.9 ± 0.1     | v4 5.6 ± 0.1           | 0.073|
| Inulin (μIU/mL)              | v1 5.8 ± 0.1     | v4 5.4 ± 0.1           | 0.012|
| Lipid (μmol/L)               | v1 3.6 ± 0.6     | v4 2.8 ± 0.5           | 0.183|
| Lipid (μmol/L)               | v1 3.5 ± 0.6     | v4 2.7 ± 0.5           | 0.344|
| Lipid (μmol/L)               | v1 15.8 ± 2.4    | v4 11.0 ± 1.4          | 0.084|
| Lipid (μmol/L)               | v1 14.5 ± 2.5    | v4 11.4 ± 1.8          | 0.333|
| Lipid (μmol/L)               | v1 402 ± 50      | v4 400 ± 41            | 0.975|
| Lipid (μmol/L)               | v1 476 ± 102     | v4 439 ± 60            | 0.640|
| Lipid (μmol/L)               | v1 1.31 ± 0.15   | v4 1.17 ± 0.13         | 0.474|
| Lipid (μmol/L)               | v1 1.13 ± 0.14   | v4 1.39 ± 0.23         | 0.346|

Values are mean ± SE. Abbreviations: ALT, alanine aminotransferase; FFAs, free fatty acids; FGF21, fibroblast growth factor 21; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance.

* FGF21, n = 7–9 in each group.

** Glucose was measured twice.

2.6. Statistical analysis

Linear correlation (two-tailed) between two variables was determined using Pearson correlation coefficient (r) and sample size. Comparisons between two data sets were made using a t-test (paired two sample for means), where p < 0.05 (two-tailed) was considered significant. Data were expressed as mean ± standard error.

3. Results

3.1. Biochemical variables in plasma

The average concentration of plasma triglycerides after empagliflozin treatment for 3 months remained unchanged. The concentrations of other common variables in plasma including metabolites, hormones and proteins were also essentially unchanged. There were no significant differences in insulin, glucagon, C-reactive protein, adiponectin and other biochemical assays (Table 2). Notably, however, HbA1c in the empagliflozin group at the final visit was lower compared to the placebo group (5.8 ± 0.1% versus 5.4 ± 0.1%, p = 0.012), but it was not significantly lower than that at the first visit in the same group (5.6 ± 0.1% versus 5.4 ± 0.1%, p = 0.229).
3.2. Changes in plasma triglycerides and body weight depending on VAT

Though the average concentration of plasma triglycerides in the empagliflozin groups was similar with that of the placebo group at the first or the final visit (Table 2), the triglyceride contents in individuals were changed after empagliflozin treatment. Two examples are shown in Fig. 2 with $^{13}$C NMR of the glycerol backbone of triglycerides from two participants; one with 1.9-kg VAT (Fig. 2C) and the other with 5.4-kg VAT (Fig. 2D). As noted, the singlet at TG-glycerol C1 & C3 reflects a triglyceride pool. The peak area of the singlet from the subject with low VAT was reduced after empagliflozin treatment while the singlet from the subject with low VAT (Fig. 2D). As noted, the total contribution was calculated based on $[U-^{13}C_3]$glycerol administration reduced in the empagliflozin group with low VAT after treatment, but tended to increase in the group with high VAT.

The body weight in the empagliflozin group after treatment tended to be lower than that of the placebo group ($p = 0.066$; Fig. 3D). Consistently, when VAT and the difference of body weight between post- and pre-treatment ($\Delta$body weight) were plotted, many participants in the empagliflozin group, notably subjects with high VAT, lost body weight (*, $p < 0.05$; $n = 16–17$ in the placebo group ($8–9$ with low VAT & $8$ with high VAT); $n = 15–18$ in the empagliflozin group ($7$ with low VAT & $8–11$ with high VAT).

3.3. Effect of VAT on total glycerol metabolism to triglycerides

The total contribution of oral glycerol to triglycerides (i.e., TG-$[^{13}C]$glycerol), the sum of indirect and direct pathways of glycerol metabolism, was not different between the placebo and empagliflozin groups. As noted, the total contribution was calculated based on $^{13}$C NMR analysis of TG-glycerol C1 and C3 (Fig. 4A). However, when stratified by VAT mass, the empagliflozin group with low VAT tended to have lower enrichment after treatment without statistical significance (Fig. 4B). Furthermore, the absolute concentrations of TG-$[^{13}C]$glycerol after empagliflozin therapy substantially decreased among subjects with low VAT and tended to increase in the group with high VAT (Fig. 4C). TG-$[^{13}C]$glycerol in the placebo group remained unchanged after three months regardless of VAT.

3.4. Effect of VAT on indirect glycerol metabolism to triglycerides

The contribution of oral glycerol to the glycerol backbone through the TCA cycle was examined by analyzing the backbone C2 in triglycerides in the empagliflozin group with high VAT tended to increase after treatment without statistical significance (Fig. 3C). The body weight in the empagliflozin group after treatment tended to be lower than that of the placebo group ($p = 0.066$; Fig. 3D). Consistently, when VAT and the difference of body weight between post- and pre-treatment ($\Delta$body weight) were plotted, many participants in the empagliflozin group, notably subjects with high VAT, lost body weight (Fig. 3E).
triglycerides (Fig. 5A). In all subjects, regardless of therapy or VAT mass, a significant fraction of glycerol contributing to the triglyceride backbone underwent metabolism through the TCA cycle prior to fatty acid esterification. Specifically, the indirect glycerol contribution to triglycerides based on TG-[13C3]glycerol appearance reached up to ~20% at 3 h after [U-13C3]glycerol administration in all groups (Fig. 5B). However, the absolute level of TG-[13C3]glycerol indicating [U-13C3]glycerol contribution to triglycerides through the TCA cycle was significantly reduced in the empagliflozin group with low VAT after treatment (Fig. 5C). Similarly, TG-[13C3]glycerol produced through glycerol direct incorporation was significantly suppressed in the empagliflozin group with low VAT after treatment (Fig. 5D). Such suppression was not detectable in the placebo group or in the empagliflozin group with high VAT.

4. Discussion

This study demonstrated that the effect of empagliflozin on triglyceride synthesis in non-diabetic adults with obesity differed depending on baseline VAT. Empagliflozin tended to decrease plasma triglyceride concentration in the subjects with low VAT, but to increase the concentration in those with high VAT. Notably, the subjects with high VAT lost body weight after empagliflozin treatment. Glycerol incorporation to triglycerides following [U-13C3]glycerol administration decreased in the empagliflozin group with low VAT while it tended to increase in the group with high VAT. Consistently, both glycerol direct incorporation and indirect incorporation through the TCA cycle to triglycerides decreased after empagliflozin treatment in the subjects with low VAT. Together these data demonstrated that treatment with empagliflozin for three months suppressed triglyceride synthesis in obese adults with low VAT and reduced lipid burden in the adults with high VAT evidenced by body weight loss (Fig. 6).

The reduction in plasma triglycerides after empagliflozin treatment was not a surprise because increased lipid utilization with SGLT2 inhibitor therapy is expected to compensate for glycosuria. From this perspective, the trend of triglyceride gain in the empagliflozin group with high VAT was unexpected and the finding seemed inconsistent with well-known beneficial effects of SGLT2 inhibitors. However, the loss of body weight was most noticeable in this population after treatment. Earlier studies with diabetic patients also reported body weight control and visceral fat decrease with empagliflozin therapy [18, 23, 40]. VAT is known to be metabolically active with a rich vascular supply and can be known to be metabolically active with a rich vascular supply and can be known to be metabolically active with a rich vascular supply and can be known to be metabolically active with a rich vascular supply and can be known to be metabolically active with a rich vascular supply.

The current finding, triglyceride or body weight reduction after empagliflozin treatment, suggests that empagliflozin may have beneficial effects even in non-diabetic adults with obesity. Further studies are needed to fully understand the mechanism of triglyceride reduction in non-diabetic adults and to explore potential applications of this novel therapeutic strategy in metabolic diseases.
Metabolism Open 13 (2022) 100161

empagliflozin treatment, is important for two reasons. First, participants were “healthy” adults with obesity, which are different from most earlier empagliflozin studies with diabetic patients. As a SGLT2 inhibitor, empagliflozin may lead to most noticeable changes with diabetic patients. Since the volunteers in this study were not hyperglycemic, metabolic changes were expected to be subtle. Nonetheless, this study found that empagliflozin relieved lipid burden in obese adults and its effect depended on baseline VAT. Second, this study provided a clue why many earlier studies reported negative results regarding the impact of empagliflozin on lipid metabolism [28–30]. The average concentration of triglycerides in this study remained unchanged with empagliflozin treatment, and even the tendency of increased triglycerides was observed in subjects with high VAT. Obesity and high VAT are risk factors for the development of T2DM [44], and the current finding from obese adults with high VAT was actually quite consistent with negative results from the earlier studies with diabetic patients. As noted, the

Fig. 5. Indirect contribution of oral glycerol to triglycerides. These results are based on analysis of TG-glycerol C2 that distinguishes glycerol indirect and direct contribution to triglycerides following [U-13C3]glycerol administration. (A) Indirect contribution of oral glycerol to triglycerides through the TCA cycle. A triplet (T) at this region is from [13C3]glycerol backbone, reflecting labeled glycerol indirect contribution to triglycerides through the TCA cycle. A doublet (D) is the signal from [13C2]glycerol backbone, reflecting labeled glycerol indirect contribution to triglycerides through the TCA cycle. (B) The percentage of [U-13C3]glycerol indirect contribution to triglycerides remained unchanged in both groups. (C-D) Both indirect and direct glycerol incorporation to triglycerides decreased in the empagliflozin group with low VAT after treatment based on the quantitation of TG-[13C2]glycerol and TG-[13C3]glycerol, respectively. Open circle = 12C; black circle = 13C; blue circle = 13C after metabolism through the TCA cycle. *, p < 0.05; n = 16 in the placebo group (8 with low VAT & 8 with high VAT); n = 15 in the empagliflozin group (7 with low VAT & 8 with high VAT). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 6. Indirect effects of empagliflozin on triglyceride (TG) synthesis. Empagliflozin enhances glycosuria by inhibiting glucose reabsorption. In obese adults after empagliflozin treatment, triglyceride synthesis following oral administration of [U-13C3]glycerol was suppressed in the subjects with low VAT while the synthesis tended to increase in those with high VAT. Since the subjects with high VAT lost body weight, the increased triglyceride synthesis was presumably associated with visceral fat lipolysis, releasing glycerol and fatty acids, to compensate for glycosuria caused by empagliflozin. Abbreviations: TCA, tricarboxylic acid cycle; VAT, visceral adipose tissue; open circle = 12C; black circle = 13C; blue circle = 13C after metabolism through the TCA cycle. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
tendency of increased triglycerides could be a consequence of lipid mobilization because the corresponding subjects lost body weight.

Monitoring $^{13}$C-labeling patterns in the backbone of triglycerides following [U-$^{13}$C$_3$]glycerol loading provided direct insight into a series of metabolic processes including hepatic triglyceride synthesis through fatty acid esterification and triglyceride release into the circulation. Triglyceride contents and the glycerol incorporation to triglycerides were consistently reduced in obese adults with low VAT after empagliflozin treatment. In addition, glycerol direct and indirect incorporation to triglycerides were conveniently distinguished based on TG-glycerol C2 analysis. As noted, double-labeled backbone in triglycerides (TG-$^{13}$C$_3$)glycerol reflects the glycerol metabolism through the TCA cycle prior to triglycerides. This process, termed glyceroneogenesis, shares metabolic pathways with gluconeogenesis including pyruvate carboxylase and phosphoenolpyruvate carboxykinase in the liver. Hepatic gluconeogenesis from the TCA cycle is the major contribution to endogenous glucose production in the body, and empagliflozin and other SGLT2 inhibitors were reported to increase the production in diabetic patients [45, 46]. Here again we see some consistency between earlier studies with diabetic patients and the current study with obese adults with high VAT because of the tendency of increased glyceroneogenesis detected in the subjects with high VAT after empagliflozin treatment.

Interestingly, $^{13}$C-enrichments in triglycerides in the low VAT groups were high at 60–90 min while the enrichments in the high VAT groups peaked somewhat later, at 90–120 min after the administration of [U-$^{13}$C$_3$]glycerol (Fig. 4B). This could be attributed to slower [U-$^{13}$C$_3$] glycerol absorption in the high VAT groups. However, a delay in the uptake of glycerol by the intestine or the liver in the high VAT groups is not likely because plasma glycerol concentrations between the low versus high VAT groups were similar after the glycerol loading (Fig. 52). In addition, the absolute concentrations of $^{13}$C-labeled triglycerides at 60 min were actually similar between the low and the high VAT groups (Fig. 4C), and the concentrations after 90 min were higher in the high VAT groups. Consistent with this interpretation, an earlier rodent study found that glycerol uptake by the liver was actually increased in obese animals [47]. Thus, a slower uptake by the intestine or the liver does not explain the delay of peaks in $^{13}$C-labeled triglycerides. Related with the delay, changes of total triglyceride contents after the glycerol loading also differed between the low versus the high VAT groups (Fig. 3C). The high VAT groups showed steadily increasing total triglycerides up to 180 min while the low VAT groups reached plateau at ~90 min. This kind of sluggish response in plasma triglycerides seems more likely a consequence of dysregulated triglyceride metabolism after the glycerol uptake. Obviously, as noted, fatty acid esterification in the high VAT groups tended to increase as evidenced with enhanced $^{13}$C-labeled triglycerides in plasma (Fig. 4C). The delay could be also related with reduced triglyceride utilization in the association with impaired fatty acid oxidation in periphery.

In summary, empagliflozin showed distinctive effects on lipid metabolism in obese non-diabetic adults depending on VAT. It suppressed triglyceride synthesis in the subjects with low VAT and led to body weight loss in those with high VAT. The tendency of increased triglycerides in the latter could be transient in association with VAT mobilization. In addition to the well-known role of empagliflozin in glycemic control for diabetic patients, this study demonstrated that it could benefit adults with obesity by ameliorating lipid burden. Three-month treatment in the current study was rather short and the long-term impact of empagliflozin on lipid metabolism in this population remains to be investigated.

**Funding**

This study was supported by the National Institutes of Health [DK099289 to ES1, DK106520 to UN, DK058398 and EB015908 to CRM, TR001105 to UT Southwestern], and UT Southwestern-Dedman Family Scholarship in Clinical Care to IJN.
Cardiovasc Med 2020;7:22. https://doi.org/10.3389/fcmr.2020.00022.

[14] Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharmacol Sci 2016;93:244-52. https://doi.org/10.1016/j.ejps.2016.08.025.

[15] Shubrook JH, Bokarie B, Adkin SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Dev Ther 2015;9:979-803. https://doi.org/10.2147/DDDT.S69926.

[16] Marx N, McGuire DK. Sodium-glucose co-transporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Heart J 2016;37(42):3192–200. https://doi.org/10.1016/j.heartearths必出.110.

[17] Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499–508. https://doi.org/10.1172/JCI72227.

[18] Shin Y, Moon JH, Chin HJ, Ferrannini E, Lim S. Glycemic efficacy and metabolic consequences of an empagliflozin add-on versus conventional dose-increasing strategy in patients with type 2 diabetes inadequately controlled by metformin and sulfonylureas. Endocrinol Metab 2020;35(3):329–38. https://doi.org/10.3803/EnM.2020.35.3.329.

[19] Rosenstock J, Senn LK, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycemia. Diabetes Obes Metab 2013;15:1154–60. https://doi.org/10.1111/dom.12185.

[20] Ozcelik S, Celik M, Vural A, Aydin B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: a real-world data. North Clin Istanbul 2020;7(2):167–73. https://doi.org/10.14774/nci.2020.02697.

[21] Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Waisr JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 2018;41(8):1801–8. https://doi.org/10.2337/dc18-0165.

[22] Sawada T, Uzu K, Hashimoto N, Onishi T, Takaya T, Shimane A, Taniguchi Y, Yaaska Y, Ohara T, Kawai H. Empagliflozin’s ameliorating effect on plasma triglycerides: association with endothelial function recovery in diabetic patients with coronary artery disease. J Atherosclerosis Thromb 2020;27(7):644–56. https://doi.org/10.5551/jat.50807.

[23] Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin improves glycemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16(2):147–58. https://doi.org/10.1111/dom.12118.

[24] Kahn S, Gancheva S, Straubinger K, Herder C, Machann J, Katsuuya H, Kabisch S, Henkel E, Kopf S, Lapergerch P, Kantartzis K, Kupriyanova Y, Markgrad P, von Gernet T, Knebel R, Wolkersdorf MF, Koss O, Wang HJ, Bornstein SR, Kasperk C, Stefan N, Flietner A, Birkenfeld AL, Roden M. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 2020;43(2):298–305. https://doi.org/10.2337/dc19-1061.

[25] Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites 2021;11(2):87. https://doi.org/10.3390/metabo11020087.

[26] Lu L, Ignacik R, Nagashima M, Zhihe F, Ni Y, Chen G, Mayoux E, Kaneko S. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. ElibioMedicine 2017;20137–49. https://doi.org/10.1016/j.bjomed.2015.05.026.

[27] Bonner C, Kerr-Conte J, Gnyre V, Queniat E, Moerman E, Thunert J, Beaumamps C, Delaunay A, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in diet-induced obese mice. EBioMedicine 2017;20:137–46. https://doi.org/10.1016/j.ebiom.2017.05.028.

[28] Kohler S, Salsalii A, Hantel S, Kupfer K, Woerle HJ, Kim G, Broedl UC. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Therapeutics 2016;38:299–313. https://doi.org/10.1016/j.clinthera.2016.03.031.

[29] Halimi S, Verges B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014;40:528–34. https://doi.org/10.1016/j.selsdm.2014.07.008.